On Jan. 16, 2012, the U.S. Food and Drug Administration (FDA) approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. This new technology may enable a faster start-up of vaccine manufacturing should a pandemic occur. Flubok is approved for people 18 through 49 years of age. Read more.
© 2022 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder.